Investigating Public Blood Supplies
Call for an Urgent Investigation of COVID-19 Vaccinated Blood and it's potential to Cause Mortal Death in Unvaccinated Individuals
Last updated
Call for an Urgent Investigation of COVID-19 Vaccinated Blood and it's potential to Cause Mortal Death in Unvaccinated Individuals
Last updated
Executive Summary
The World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic in 2020, following which a global genetic vaccination program has been rapidly implemented as a fundamental solution. However, it has been reported worldwide that the modified mRNAs encoding spike proteins and lipid nanoparticles, which are used as drug delivery systems, not only cause thrombosis and cardiovascular disorders post vaccination, but might also cause diverse diseases involving all organs and systems, including the nervous system. The concern is that these spike protein and DNA contamination can continue onward into the public blood bank supply and must be urgently investigated.
References: https://www.preprints.org/manuscript/202403.0881/v2
A Japanese preprint study warned of risks in transfusing blood from COVID vaccine recipients to other patients, indicating it may cause significant health risks, including death. The researchers also call for safety measures to screen and secure the world’s blood supply.
Netherlands: Woman (63 years old) dies from blood clots 5 days after transfusion Emser, 63, died from blood clots in her lungs and legs five days after receiving a blood transfusion. The Other Newspaper wrote that the incident was reported to Sanquin but the blood bank suppressed the report. When she needed a blood transfusion, she asked the doctors and Sanquin for a transfusion of unvaccinated blood. The doctors and the blood bank did not want to cooperate. All blood is safe,” they said. “I am confident that the embolism in the lungs and legs is a direct result of the blood transfusion,” the nurse said.
Titled Transfusions of Blood Products Derived from Genetic Vaccine Recipients: Safety Concerns and Proposals for Specific Measures, the paper’s second version posted Wednesday recalls the “global genetic vaccination program” that had been “rapidly implemented as a fundamental solution” to the coronavirus disease in 2020. The paper’s abstract continues:
However, it has been reported worldwide that the modified mRNAs encoding spike proteins and lipid nanoparticles, which are used as drug delivery systems, not only cause thrombosis and cardiovascular disorders post vaccination, but might also cause diverse diseases involving all organs and systems, including the nervous system.Based on these reports and the abundant evidence that has come to light in the past few years, this paper aims to draw the attention of medical professionals to the various risks associated with transfusion using blood products derived from long COVID patients or from genetic vaccine recipients, and to make proposals regarding specific inspection items, testing methods, regulations, etc.
In his commentary on the relevance of the study, Dr. Joseph Mercola highlighted the paper’s particular attention to the dangers such transfusions may have on neurological health. Blood infected with “prion-like structures” found within the spike protein, produced by these injections, may induce “the misfolding of normal proteins in the brain,” causing disorders.
“Prion diseases are characterized by a long incubation period, followed by rapid progression and high mortality,” he wrote. And the possibility that these spike proteins may include “prion-like domains” raises several concerns.
These include the risk of transmitting of such prion-like structures through blood transfusions with the risk of causing dangerous prion disease in recipients.
“Prion diseases are notoriously difficult to diagnose early, have no cure, and are fatal, making any potential transmission through blood products a significant safety concern,” Mercola wrote.
Furthermore, due to technical challenges and the historical rarity of prion disease, current screening processes do not test for these structures and may thus be inadequate in preventing such transmission.
And since prion diseases have long latency periods, meaning their symptoms may only present after years or decades from actual exposure, this “delay complicates efforts to trace the source of an infection back to a blood transfusion and assess the safety of blood supplies over time,” the osteopathic physician summarized.
All of this may affect the confidence of the public in the safety of blood transfusions, and naturally necessitate changes in donor eligibility criteria, including the establishment of additional screening protocols.
References:
